CoChat

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men

Peura, Piia, Martikainen, Janne, Soini, Erkki, Hallinen, Taru, Niskanen, Leo · 2008 · Current Medical Research and Opinion

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study evaluated the long-term cost-effectiveness of atorvastatin 20 mg, rosuvastatin 10 mg and simvastatin 40 mg in primary and secondary prevention of CHD in Finland. RESEARCH DESIGN AND METHODS: The effect of statin therapy on the incidence of CHD and the expected total costs of the disease were described using a Markov state transition model. Due to the limited amount of evidence concerning mortality and morbidity for rosuvastatin, the model was used to transmute the efficiency data of all statins (decrease in total cholesterol) into long-term endpoints (myocardial infarction, death) using risk functions of the FINRISK and 4S studies. The study followed a characterized cohort of 55-year-old Finnish men with an average 3.3-6.6% baseline risk of dying from cardiovascular disease within a 10-year period. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs) for atorvastatin and rosuvastatin, compared with simvastatin, measured as cost of life years gained (euro/LYG) and cost of quality adjusted life years gained (euro/QALY). RESULTS: The use of rosuvastatin increased the life expectancy by 0.27 years on average (LYG) compared with simvastatin, producing additional 0.08 quality-adjusted life-years (QALYs). Compared with simvastatin, the cost of one LYG with rosuvastatin was euro10 834 and the cost of one QALY gained was euro36 548 (discount rate 5% per annum). Corresponding figures for atorvastatin were euro31 286/LYG and euro105 599/QALY. CONCLUSIONS: If the decision makers' willingness to pay for a QALY gained is around euro40 000 there is a high probability (>50%) that rosuvastatin represents a cost-effective form of therapy in the prevention of CHD in middle-aged men with an average 3.3-6.6% risk of dying within 10 years from cardiovascular disease. However, the true clinical impact of these results needs confirmation from on-going clinical trials, as the role of rosuvastatin in reducing clinical events is pending, but for simvastatin and atorvastatin established.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990802144705

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 6

  1. National Agency for Medicines and Social Insurance Institution, 2007, Finnish statistics on medicines 2006
  2. Davies A, 2006, Br J Cardiol, 13, 196
  3. Statistic Finland, 2002, Causes of death 2001
  4. Finnish National Public Health Institute, National cardiovascular disease register
  5. Hujanen T, 2003, Terveydenhuollon Yksikkökustannukset Suomessa Vuonna 2001. Aiheita 1/2003
  6. Väistö T, 2005, Finnish Med J, 60, 389

Cited by

See all 29

Metadata

Authors
Peura, P., Martikainen, J., Soini, E., Hallinen, T., & Niskanen, L.
Affiliations
  • University of Eastern Finland (FI)
  • ESiOR Oy (Finland) (FI)
  • Kuopio University Hospital (FI)
Corresponding author
Peura, Piia
Venue
Current Medical Research and Opinion
Published
2008-05-14
Volume
24
Issue
6
Pages
1823-1832
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2142140912
Cited by
29
References
25
Citations by year
2026: 1 · 2025: 1 · 2020: 1 · 2019: 4 · 2017: 6 · 2016: 4 · 2015: 1 · 2014: 1
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
statins, cost-effectiveness, coronary heart disease prevention, rosuvastatin, atorvastatin, simvastatin, middle-aged men, cardiovascular risk, quality-adjusted life years, life-years gained, cardiovascular mortality, myocardial infarction, Finnish men
MeSH terms
Rosuvastatin Calcium, Atorvastatin, Coronary Disease, Cost-Benefit Analysis, Finland, Fluorobenzenes, Heptanoic Acids, Humans, Life Expectancy, Male, Markov Chains, Middle Aged, Pyrimidines, Pyrroles, Sulfonamides, Cohort Studies, Quality-Adjusted Life Years, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. https://app.cochat.ai/papers/10.1185/03007990802144705
The paper
Peura, P., Martikainen, J., Soini, E., Hallinen, T., & Niskanen, L. (2008). Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802144705

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.